Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial

Additional evidence against widespread use of inpatient antiplatelet therapy in coronavirus infection: data from a randomized controlled trial

.

Saved in:

Bibliographic Details
Main Author:	I. S. Yavelov
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2022-02-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	covid-19 coronavirus infection antiplatelet agents acetylsalicylic acid p2y12 inhibitors clopidogrel ticagrelor
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/3196
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015-12-01)

Ticagrelor vs. clopidogrel in dual antiplatelet therapy after coronary artery bypass surgery: a meta-analysis
by: Liyuan Wang, et al.
Published: (2025-05-01)

Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01)

EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?
by: Roman M. Shakhnovich
Published: (2018-12-01)

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01)

Use of antiplatelet agents in patients after myocardial infarction followed up in Moscow outpatient clinics. Results of a non-interventional prospective study
by: A. I. Sapina, et al.
Published: (2024-04-01)

Double antiplatelet therapy in patients with acute coronary syndrome
by: A. V. Rodionov, et al.
Published: (2011-10-01)

PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW
by: I. S. Yavelov
Published: (2017-09-01)

High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice
by: N. F. Puchinyan, et al.
Published: (2016-09-01)

Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01)

The Effects of Dual Antiplatelet Therapy on the Occurrence of Recurrent Cardiovascular Events After Myocardial Infarction in Obese Patients
by: Borovyk K., et al.
Published: (2019-04-01)

Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013
by: O. V. Averkov
Published: (2013-02-01)

The types and durations of antiplatelet drugs for symptomatic vertebrobasilar artery stenosis: a retrospective study
by: Xi Liu, et al.
Published: (2025-04-01)

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

SOME ASPECTS OF IMPROVING ADHERENCE TO DUAL ANTITHROMBOTIC THERAPY AFTER ACUTE CORONARY SYNDROME
by: A. D. Erlikh
Published: (2017-05-01)

UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE
by: S. Yu. Martsevich, et al.
Published: (2015-12-01)

Antiplatelet Therapy and Platelet Activity Testing for Neurointerventional Procedures
by: Keiko A Fukuda, et al.
Published: (2025-01-01)

ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: THE PROBLEM OF EFFICIENCY, SAFETY AND COMPLIANCE
by: S. Yu. Martsevich, et al.
Published: (2014-07-01)

ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE
by: S. R. Gilyarevskiy, et al.
Published: (2015-12-01)

Antiplatelet drug resistance in patients with coronary heart disease
by: V. A. Sulimov, et al.
Published: (2012-12-01)

Real-time platelet P2Y12 receptor occupancy as a promising pharmacodynamics biomarker for bridging the gap between PK/PD of clopidogrel therapy
by: Haipeng Li, et al.
Published: (2025-01-01)

THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS
by: O. V. Gaisenok
Published: (2016-01-01)

EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: A. L. Alyavi, et al.
Published: (2016-01-01)

INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION
by: E. V. Tavlueva, et al.
Published: (2017-11-01)

P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel
by: N. M. Vorobyeva
Published: (2019-01-01)

Antiplatelet treatment and gastro-intestinal hemorrhage risk
by: D. V. Duplyakov
Published: (2005-08-01)

Dual versus single antiplatelet therapy in patients with nonminor ischemic stroke: a meta-analysis
by: Izabela Orlandi Môro, et al.
Published: (2025-02-01)

Does the level of myocardial injury differ in primary angioplasty patients loaded first with clopidogrel and the ones with ticagrelor?
by: Nil Ozyuncu, et al.
Published: (2020-07-01)

ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES
by: E. V. Konstantinova, et al.
Published: (2018-07-01)

Impact of antiplatelet therapy on hemostatic plug formation in the setting of thrombocytopenia
by: Robert H. Lee, et al.
Published: (2025-01-01)

Dual Antiplatelet Therapy Regimens and Duration for Intracranial Stenting Procedures: Literature Review
by: Milda Paliulytė, et al.
Published: (2023-11-01)

MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: N. F. Puchinian, et al.
Published: (2017-03-01)

POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: O. V. Sirotkina, et al.
Published: (2015-09-01)

Abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials
by: Hamidreza Soleimani, et al.
Published: (2025-04-01)

Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA stratified by age and renal function: CHANCE-2 trial substudy
by: Yu Wu, et al.
Published: (2025-12-01)

ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION
by: D. H. Ainetdinova, et al.
Published: (2016-01-01)

SYNTHESIS, ANTIAGGREGATION AND ANTITROMBOTIC ACTIVITIES OF NEW DERIVATIVES OF HYDROXYBENZOIC ACIDS WITH TAURIC FRAGMENT
by: A. K. Brel, et al.
Published: (2021-08-01)

Impact of health education on adherence to clopidogrel and clinical effectiveness of antiplatelet treatment in patients after myocardial infarction
by: Aldona Kubica, et al.
Published: (2015-12-01)

ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY?
by: S. J. Martsevich
Published: (2016-01-01)

Efficacy and Safety of Dual Antiplatelet Therapy Using Cilostazol with Aspirin or Clopidogrel to Reduce the Rate of Recurrent Ischemic Stroke in Asia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Hendrawan Chandra Kusuma, et al.
Published: (2025-05-01)